Literature DB >> 28050668

Antibiotics May be Safely Discontinued Within One Week of Percutaneous Cholecystostomy.

Tyler J Loftus1, Scott C Brakenridge1,2, Camille G Dessaigne1, George A Sarosi1,3, William J Zingarelli1,3, Frederick A Moore1,2, Janeen R Jordan1, Chasen A Croft1, R Stephen Smith1, Phillip A Efron1,2, Alicia M Mohr4,5.   

Abstract

BACKGROUND: For patients with acute cholecystitis managed with percutaneous cholecystostomy (PC), the optimal duration of post-procedural antibiotic therapy is unknown. Our objective was to compare short versus long courses of antibiotics with the hypothesis that patients with persistent signs of systemic inflammation 72 h following PC would receive prolonged antibiotic therapy and that antibiotic duration would not affect outcomes.
METHODS: We performed a retrospective cohort analysis of 81 patients who underwent PC for acute cholecystitis at two hospitals during a 41-month period ending November 2014. Patients who received short (≤7 day) courses of post-procedural antibiotics were compared to patients who received long (>7 day) courses. Treatment response to PC was evaluated by systemic inflammatory response syndrome (SIRS) criteria. Logistic and linear regressions were used to evaluate associations between antibiotic duration and outcomes.
RESULTS: Patients who received short (n = 30) and long courses (n = 51) of antibiotics had similar age, comorbidities, severity of cholecystitis, pre-procedural vital signs, treatment response, and culture results. There were no differences in recurrent cholecystitis (13 vs. 12%), requirement for open/converted to open cholecystectomy (23 vs. 22%), or 1-year mortality (20 vs. 18%). On logistic and linear regressions, antibiotic duration as a continuous variable was not predictive of any salient outcomes.
CONCLUSIONS: Patients who received short and long courses of post-PC antibiotics had similar baseline characteristics and outcomes. Antibiotic duration did not predict recurrent cholecystitis, interval open cholecystectomy, or mortality. These findings suggest that antibiotics may be safely discontinued within one week of uncomplicated PC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28050668      PMCID: PMC5395343          DOI: 10.1007/s00268-016-3861-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

1.  Treatment of acute cholecystitis in non-critically ill patients at high surgical risk: comparison of clinical outcomes after gallbladder aspiration and after percutaneous cholecystostomy.

Authors:  S Chopra; G D Dodd; A L Mumbower; K N Chintapalli; W H Schwesinger; K R Sirinek; J P Dorman; H Rhim
Journal:  AJR Am J Roentgenol       Date:  2001-04       Impact factor: 3.959

2.  An antibiotic policy to prevent emergence of resistant bacilli.

Authors:  P de Man; B A Verhoeven; H A Verbrugh; M C Vos; J N van den Anker
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

3.  Quality improvement guidelines for percutaneous transhepatic cholangiography, biliary drainage, and percutaneous cholecystostomy.

Authors:  Wael E A Saad; Michael J Wallace; Joan C Wojak; Sanjoy Kundu; John F Cardella
Journal:  J Vasc Interv Radiol       Date:  2010-03-21       Impact factor: 3.464

4.  Percutaneous cholecystostomy is an effective definitive treatment option for acute acalculous cholecystitis.

Authors:  J Kirkegård; T Horn; S D Christensen; L P Larsen; A R Knudsen; F V Mortensen
Journal:  Scand J Surg       Date:  2015-01-07       Impact factor: 2.360

5.  Gangrenous cholecystitis: analysis of risk factors and experience with laparoscopic cholecystectomy.

Authors:  L T Merriam; S A Kanaan; L G Dawes; P Angelos; J B Prystowsky; R V Rege; R J Joehl
Journal:  Surgery       Date:  1999-10       Impact factor: 3.982

Review 6.  Antibiotic stewardship in the intensive care unit.

Authors:  Heather M Arnold; Scott T Micek; Lee P Skrupky; Marin H Kollef
Journal:  Semin Respir Crit Care Med       Date:  2011-04-19       Impact factor: 3.119

7.  Biliary microflora in patients undergoing cholecystectomy.

Authors:  Bahman Darkahi; Gabriel Sandblom; Håkan Liljeholm; Per Videhult; Åsa Melhus; Ib Christian Rasmussen
Journal:  Surg Infect (Larchmt)       Date:  2014-05-06       Impact factor: 2.150

8.  Percutaneous cholecystostomy for acute cholecystitis in patients with high comorbidity and re-evaluation of treatment efficacy.

Authors:  Ye Rim Chang; Young-Joon Ahn; Jin-Young Jang; Mee Joo Kang; Wooil Kwon; Woo Hyun Jung; Sun-Whe Kim
Journal:  Surgery       Date:  2014-01-11       Impact factor: 3.982

9.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

Review 10.  Financial evaluations of antibiotic stewardship programs-a systematic review.

Authors:  Jan-Willem H Dik; Pepijn Vemer; Alex W Friedrich; Ron Hendrix; Jerome R Lo-Ten-Foe; Bhanu Sinha; Maarten J Postma
Journal:  Front Microbiol       Date:  2015-04-16       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.